Hereditary ATTR


Plasma biomarkers may help differentiate TTR V142I carriers from noncarriers in young preclinical cases. Read More ›

The T60A variant of hATTR presents with a high prevalence of neurologic manifestations that are more frequent at an earlier stage than cardiac manifestations. Read More ›


Clinicians need to be aware of potential signals of hereditary transthyretin amyloidosis that most commonly present in the year before diagnosis. Read More ›

Focusing on the prevalence of the Val122Ile mutation in African-American patients with hereditary transthyretin cardiac amyloidosis may lead to underestimation of this condition in this population. Read More ›

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.

I'd like to receive: